QuidelOrtho revised its respiratory diagnostic sales forecast downward due to the absence of an anticipated summer Covid surge, although it reaffirmed full-year revenue guidance. CFO Joe Busky cited lower hospitalizations and emergency visits as signs of less severe circulating viral strains, dampening test utilization. Meanwhile, the company expects reduced tariff impacts will offset revenue declines. QuidelOrtho continues awaiting results on regulatory reviews of point-of-care molecular testing systems to expand its diagnostics portfolio.